Standard treatments for advanced NSCLC include systemic chemotherapy, molecularly targeted therapies (e.g., estimated glomerular filtration rate (EGFR) or anaplastic lymphoma kinase (ALK) inhibitors), and immunotherapy [16]. Here, ALK is linked to non-small cell lung carcinoma.